In the Original Article entitled, “Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal Bleeding” published in the February 2018 issue of Mayo Clinic Proceedings (Mayo Clin Proc. 2018;93(2):155-166), an error is present in Table 4. In the Variable for All patients (N=34), Any transfusion, n (%), under Before bevacizumab treatment at 6 mo, the value should be 16 (47).
Article Info
Identification
Copyright
© 2017 Mayo Foundation for Medical Education and Research
ScienceDirect
Access this article on ScienceDirectLinked Article
- Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal BleedingMayo Clinic ProceedingsVol. 93Issue 2
